Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240013/S028

Sphere-9 Catheter and Affera Ablation System

Medtronic, Inc. · Decision date Oct 6, 2026

MEDTECHLEDGER EXPLANATIONP240013/S028

What did the FDA approve?

On 2026-10-06, FDA recorded an approval decision for P240013/S028, a Real-Time Process supplement to the Sphere-9 Catheter™ and Affera™ Ablation System from Medtronic, Inc. The supplement reason is listed as a labeling change covering indications, instructions, shelf life or tradename. The recorded scope is limited to modifications to the packaging and labeling of the Sphere-9 Catheter and a Predetermined Change Control Plan to extend device shelf life from 13 months to 25 months.

This action amends the existing PMA rather than approving the system anew. The device category is a percutaneous cardiac ablation catheter for treatment of atrial fibrillation with irreversible electroporation, in the cardiovascular specialty under product code QZI. The source record includes no supporting documents, so the specific labeling revisions, the content of the change control plan and any clinical data behind the shelf-life extension are not described here and remain unknown.

FDA approval order statement

Approval for modifications to the packaging and labeling of the Sphere-9 Catheter and a Predetermined Change Control Plan to extend the shelf life of the device from 13 months to 25 months.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Oct 6, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240013/S028
Regulatory pathway
PMA supplement
Product code
QZI
Decision code
APPR
Decision date
Oct 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Product code
QZI
FDA device class
3

For the original device and its historical approval scope, see PMA P240013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240013 · Original PMA

    Sphere-9 Catheter and Affera Ablation System

  2. P240013/S028 received

    Application receipt date recorded by FDA.

  3. P240013/S031 · Related supplement

    Sphere-9 Catheter and Affera Ablation System

  4. P240013/S028 · FDA decision

    Real-Time Process

  5. P240013/S032 · Related supplement

    Affera Sphere-9 Mapping and Ablation Catheter

Timeline entries are records held by MedtechLedger for P240013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240013

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalOct 24, 2024FDA
Medtronic, Inc.PMA supplementOct 2, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA
Kardium, Inc.PMA supplementOct 27, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records